Cargando…
Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
BACKGROUND: Toripalimab and anlotinib have shown good response in esophageal cancer, with high objective response rate and progression free survival. Thus, they have been approved as second-line or above-line therapy for advanced or unresectable esophageal carcinoma. Combination of these two drugs m...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601004/ https://www.ncbi.nlm.nih.gov/pubmed/37900244 http://dx.doi.org/10.12998/wjcc.v11.i27.6579 |
_version_ | 1785126103125327872 |
---|---|
author | Chen, Si-Cong Ma, Dong-Heng Zhong, Jia-Jian |
author_facet | Chen, Si-Cong Ma, Dong-Heng Zhong, Jia-Jian |
author_sort | Chen, Si-Cong |
collection | PubMed |
description | BACKGROUND: Toripalimab and anlotinib have shown good response in esophageal cancer, with high objective response rate and progression free survival. Thus, they have been approved as second-line or above-line therapy for advanced or unresectable esophageal carcinoma. Combination of these two drugs may have synergistic effects, but evidence of which is lacking. CASE SUMMARY: Here, we report on a 73-year-old male, newly diagnosed with advanced esophageal squamous cell carcinoma (ESCC), who received a combination of toripalimab and anlotinib. Complete response was achieved after treatment for 3 mo and remission was maintained up to 14 mo. CONCLUSION: The combination therapy of toripalimab and anlotinib is a promising treatment for unresectable ESCC and related clinical trials are warranted. |
format | Online Article Text |
id | pubmed-10601004 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-106010042023-10-27 Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report Chen, Si-Cong Ma, Dong-Heng Zhong, Jia-Jian World J Clin Cases Case Report BACKGROUND: Toripalimab and anlotinib have shown good response in esophageal cancer, with high objective response rate and progression free survival. Thus, they have been approved as second-line or above-line therapy for advanced or unresectable esophageal carcinoma. Combination of these two drugs may have synergistic effects, but evidence of which is lacking. CASE SUMMARY: Here, we report on a 73-year-old male, newly diagnosed with advanced esophageal squamous cell carcinoma (ESCC), who received a combination of toripalimab and anlotinib. Complete response was achieved after treatment for 3 mo and remission was maintained up to 14 mo. CONCLUSION: The combination therapy of toripalimab and anlotinib is a promising treatment for unresectable ESCC and related clinical trials are warranted. Baishideng Publishing Group Inc 2023-09-26 2023-09-26 /pmc/articles/PMC10601004/ /pubmed/37900244 http://dx.doi.org/10.12998/wjcc.v11.i27.6579 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Case Report Chen, Si-Cong Ma, Dong-Heng Zhong, Jia-Jian Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report |
title | Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report |
title_full | Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report |
title_fullStr | Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report |
title_full_unstemmed | Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report |
title_short | Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report |
title_sort | combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601004/ https://www.ncbi.nlm.nih.gov/pubmed/37900244 http://dx.doi.org/10.12998/wjcc.v11.i27.6579 |
work_keys_str_mv | AT chensicong combinationtherapywithtoripalimabandanlotinibinadvancedesophagealsquamouscellcarcinomaacasereport AT madongheng combinationtherapywithtoripalimabandanlotinibinadvancedesophagealsquamouscellcarcinomaacasereport AT zhongjiajian combinationtherapywithtoripalimabandanlotinibinadvancedesophagealsquamouscellcarcinomaacasereport |